Who was studied, and how
Two numbers in the abstract
Where each one falls
Where it lands on the map
233people with type 2 diabetes, in this paper
The trial randomly assignedassigned by chance
canagliflozin
glimepiride
No clear effect on NT-proBNP levels−74.7
randomisedAmong preserved LVEF, the trial randomly assignedassigned by chance
canagliflozin
glimepiride
No clear effect on NT-proBNP levels−58.3
randomisedthe abstract, start to end
… group [adjusted group difference; -74.7 pg/mL (95% CI, -159.3 to 10.9), P = 0.087] and also in the subgroup with preserved LVEF [-58.3 (95% CI, -127.6 to 11.0, P = …
← favours treatmentfavours comparator →
could be chanceNT-proBNP levelscanagliflozin vs glimepiride
−74.7−159 to 10.9
NT-proBNP levelscanagliflozin vs glimepiride, in preserved LVEF
−58.3−128 to 11.0
SGLT2 inhibitorsCardiac & vascular function
1 / 4